Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Change in pulmonary function · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure severity · people with ADHD and epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · people with ADHD and epilepsy
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tear film stability · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at 1‐month · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review